MedTrace Logo

IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

NCT04826159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2025-06-29

No results posted yet for this study

Summary

The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability

Conditions

  • Type 2 Diabetes
  • Diabetic Cardiomyopathies
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

IMB-1018972

Modified release tablet for oral administration

Sponsors & Collaborators

  • University of Oxford

    collaborator OTHER

  • Imbria Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Arash Yavari, BSc, MBBS, DPhil · Imbria Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-21
Primary Completion
2024-08-06
Completion
2024-08-06
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826159 on ClinicalTrials.gov